Novartis-Tourmaline Bio deal receives US antitrust clearance
Pharmaceutical company Novartis has received US antitrust clearance for its $1.4 billion acquisition of biotech company Tourmaline Bio. The companies disclosed that the waiting period under the Hart-Scott-Rodino Act expired on...To view the full article, register now.
Already a subscriber? Click here to view full article